HOXD10 and breast carcinoma: HOXD1 has been validated as a biomarker for diagnosis and prognosis of breast cancer via a functional hypermethylome screen [30], while HOXD10, as a direct target of miR-10b, suppresses cell migration and invasion in various types of cancer [31–34].